<code id='D4ADE26A39'></code><style id='D4ADE26A39'></style>
    • <acronym id='D4ADE26A39'></acronym>
      <center id='D4ADE26A39'><center id='D4ADE26A39'><tfoot id='D4ADE26A39'></tfoot></center><abbr id='D4ADE26A39'><dir id='D4ADE26A39'><tfoot id='D4ADE26A39'></tfoot><noframes id='D4ADE26A39'>

    • <optgroup id='D4ADE26A39'><strike id='D4ADE26A39'><sup id='D4ADE26A39'></sup></strike><code id='D4ADE26A39'></code></optgroup>
        1. <b id='D4ADE26A39'><label id='D4ADE26A39'><select id='D4ADE26A39'><dt id='D4ADE26A39'><span id='D4ADE26A39'></span></dt></select></label></b><u id='D4ADE26A39'></u>
          <i id='D4ADE26A39'><strike id='D4ADE26A39'><tt id='D4ADE26A39'><pre id='D4ADE26A39'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:hotspot    Page View:9748
          BiTE Bridge
          Illustration of a BiTE, Amgen's bispecific antibodies Amgen

          In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

          Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

          advertisement

          “We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In